{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:25:29Z","timestamp":1778642729454,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Program","award":["KGM1012521 and KGM1312511"],"award-info":[{"award-number":["KGM1012521 and KGM1312511"]}]},{"name":"the National Research Foundation of Korea grant funded by the Korea government","award":["2023R1A2C1004975"],"award-info":[{"award-number":["2023R1A2C1004975"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In Parkinson\u2019s disease (PD), long-term 3,4-dihydroxy-L-phenylalanine (L-dopa) therapy leads to the development of motor complications, including L-dopa-induced dyskinesia (LID). Increased numbers of reactive astrocytes in the brains of patients with PD are a key feature of this disease. Astrocytes are involved in the development of LID; however, whether the regulation of astrocytic activity influences LID development remains unclear. Therefore, this study aimed to determine the effect of the direct modulation of glial fibrillary acidic protein (GFAP)-expressing glia on LID development during L-dopa therapy in PD using chemogenetic tools. Adeno-associated viruses (AAVs) were used to target designer receptors exclusively activated by designer drugs (DREADDs) in GFAP-expressing cells to modulate Gq- or Gi-mediated signaling and regulate astrocytic activity in the brain. AAVs were injected into the dorsal striatum, and 6-hydroxydopamine (6-OHDA) was injected into the substantia nigra of mice. Clozapine N-oxide was co-administered with L-dopa. Chemogenetic activation of astrocytes in the dopamine-depleted striatum affected the early development of LID in 6-OHDA-lesioned mice. Furthermore, astrocyte suppression through Gi-mediated DREADD reduced abnormal involuntary movement scores in mice. These results suggest that regulating astrocytic activity in the dorsal striatum could be a therapeutic option for LID in PD.<\/jats:p>","DOI":"10.1038\/s41598-025-12104-5","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T14:49:45Z","timestamp":1753195785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Regulating astrocytic activity in the dorsal striatum mitigates L-dopa-induced dyskinesia in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Young-Kyoung","family":"Ryu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye-Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Hee","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung-Shim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"12104_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/bmb\/ldn013","volume":"86","author":"CA Davie","year":"2008","unstructured":"Davie, C. A. A review of Parkinson\u2019s disease. Br Med Bull 86, 109\u2013127 (2008).","journal-title":"Br Med Bull"},{"key":"12104_CR2","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"W Dauer","year":"2003","unstructured":"Dauer, W. & Przedborski, S. Parkinson\u2019s disease: Mechanisms and models. Neuron 39, 889\u2013909 (2003).","journal-title":"Neuron"},{"key":"12104_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1212\/WNL.40.2.340","volume":"40","author":"JG Nutt","year":"1990","unstructured":"Nutt, J. G. Levodopa-induced dyskinesia: Review, observations, and speculations. Neurology 40, 340\u2013345 (1990).","journal-title":"Neurology"},{"key":"12104_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1358\/dot.2015.51.5.2313726","volume":"51","author":"S Mazzucchi","year":"2015","unstructured":"Mazzucchi, S., Frosini, D., Bonuccelli, U. & Ceravolo, R. Current treatment and future prospects of dopa-induced dyskinesias. Drugs Today (Barc) 51, 315\u2013329 (2015).","journal-title":"Drugs Today (Barc)"},{"key":"12104_CR5","doi-asserted-by":"publisher","first-page":"e0237472","DOI":"10.1371\/journal.pone.0237472","volume":"15","author":"JY Hong","year":"2020","unstructured":"Hong, J. Y. et al. Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson\u2019s disease. PLoS ONE 15, e0237472 (2020).","journal-title":"PLoS ONE"},{"key":"12104_CR6","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.neuron.2008.09.004","volume":"59","author":"C Agulhon","year":"2008","unstructured":"Agulhon, C. et al. What is the role of astrocyte calcium in neurophysiology?. Neuron 59, 932\u2013946 (2008).","journal-title":"Neuron"},{"key":"12104_CR7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.neuron.2014.02.007","volume":"81","author":"A Araque","year":"2014","unstructured":"Araque, A. et al. Gliotransmitters travel in time and space. Neuron 81, 728\u2013739 (2014).","journal-title":"Neuron"},{"key":"12104_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27103194","author":"A Rauf","year":"2022","unstructured":"Rauf, A. et al. Neuroinflammatory markers: Key indicators in the pathology of neurodegenerative diseases. Molecules https:\/\/doi.org\/10.3390\/molecules27103194 (2022).","journal-title":"Molecules"},{"key":"12104_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/01.WCB.0000044631.80210.3C","volume":"23","author":"Y Chen","year":"2003","unstructured":"Chen, Y. & Swanson, R. A. Astrocytes and brain injury. J. Cereb. Blood Flow Metab. 23, 137\u2013149 (2003).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"12104_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00401-009-0619-8","volume":"119","author":"MV Sofroniew","year":"2010","unstructured":"Sofroniew, M. V. & Vinters, H. V. Astrocytes: biology and pathology. Acta Neuropathol. 119, 7\u201335 (2010).","journal-title":"Acta Neuropathol."},{"key":"12104_CR11","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1007\/s00018-020-03584-x","volume":"77","author":"AV Domingues","year":"2020","unstructured":"Domingues, A. V. et al. Glial cells in Parkinson s disease: protective or deleterious?. Cell Mol. Life Sci. 77, 5171\u20135188 (2020).","journal-title":"Cell Mol. Life Sci."},{"key":"12104_CR12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.expneurol.2007.05.014","volume":"209","author":"MT Fitch","year":"2008","unstructured":"Fitch, M. T. & Silver, J. CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure. Exp. Neurol. 209, 294\u2013301 (2008).","journal-title":"Exp. Neurol."},{"key":"12104_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ejn.13482","volume":"45","author":"AR Carta","year":"2017","unstructured":"Carta, A. R. et al. l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?. Eur. J. Neurosci. 45, 73\u201391 (2017).","journal-title":"Eur. J. Neurosci."},{"key":"12104_CR14","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.11856","author":"YK Ryu","year":"2021","unstructured":"Ryu, Y. K. et al. beta-Lapachone ameliorates L-DOPA-induced dyskinesia in a 6-OHDA-induced mouse model of Parkinson\u2019s disease. Mol. Med. Rep. https:\/\/doi.org\/10.3892\/mmr.2021.11856 (2021).","journal-title":"Mol. Med. Rep."},{"key":"12104_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.nbd.2014.10.017","volume":"73","author":"M Bortolanza","year":"2015","unstructured":"Bortolanza, M. et al. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson\u2019s disease. Neurobiol Dis. 73, 377\u2013387 (2015).","journal-title":"Neurobiol Dis."},{"key":"12104_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neuroscience.2023.02.004","volume":"523","author":"Y Yuan","year":"2023","unstructured":"Yuan, Y. et al. ONO-2506 can delay levodopa-induced dyskinesia in the early stage. Neuroscience 523, 61\u201379 (2023).","journal-title":"Neuroscience"},{"key":"12104_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.expneurol.2016.09.013","volume":"286","author":"G Mulas","year":"2016","unstructured":"Mulas, G. et al. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson\u2019s disease. Exp. Neurol. 286, 83\u201392 (2016).","journal-title":"Exp. Neurol."},{"key":"12104_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/syn.21941","volume":"70","author":"E Del-Bel","year":"2016","unstructured":"Del-Bel, E., Bortolanza, M., Dos-Santos-Pereira, M., Bariotto, K. & Raisman-Vozari, R. l-DOPA-induced dyskinesia in Parkinson\u2019s disease: Are neuroinflammation and astrocytes key elements?. Synapse 70, 479\u2013500 (2016).","journal-title":"Synapse"},{"key":"12104_CR19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.neuron.2016.01.040","volume":"89","author":"BL Roth","year":"2016","unstructured":"Roth, B. L. DREADDs for neuroscientists. Neuron 89, 683\u2013694 (2016).","journal-title":"Neuron"},{"key":"12104_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev-neuro-071013-014048","volume":"37","author":"SM Sternson","year":"2014","unstructured":"Sternson, S. M. & Roth, B. L. Chemogenetic tools to interrogate brain functions. Annu. Rev. Neurosci. 37, 387\u2013407 (2014).","journal-title":"Annu. Rev. Neurosci."},{"key":"12104_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.brainres.2012.09.043","volume":"1511","author":"MS Farrell","year":"2013","unstructured":"Farrell, M. S. & Roth, B. L. Pharmacosynthetics: Reimagining the pharmacogenetic approach. Brain Res. 1511, 6\u201320 (2013).","journal-title":"Brain Res."},{"key":"12104_CR22","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1073\/pnas.0700293104","volume":"104","author":"BN Armbruster","year":"2007","unstructured":"Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S. & Roth, B. L. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc. Natl. Acad. Sci. U S A 104, 5163\u20135168 (2007).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"12104_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.neurobiolaging.2023.01.007","volume":"125","author":"RL Suthard","year":"2023","unstructured":"Suthard, R. L. et al. Chronic Gq activation of ventral hippocampal neurons and astrocytes differentially affects memory and behavior. Neurobiol. Aging 125, 9\u201331 (2023).","journal-title":"Neurobiol. Aging"},{"key":"12104_CR24","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.18716","author":"N Chen","year":"2016","unstructured":"Chen, N. et al. Direct modulation of GFAP-expressing glia in the arcuate nucleus bi-directionally regulates feeding. Elife https:\/\/doi.org\/10.7554\/eLife.18716 (2016).","journal-title":"Elife"},{"key":"12104_CR25","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412 (2010).","journal-title":"PLoS Biol."},{"key":"12104_CR26","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2025.13496","author":"JE Kim","year":"2025","unstructured":"Kim, J. E. et al. Water extract of Humulus japonicusimproves age-related cognitive decline by inhibiting acetylcholinesterase activity and the acetylcholine signaling pathway. Mol. Med. Rep. https:\/\/doi.org\/10.3892\/mmr.2025.13496 (2025).","journal-title":"Mol. Med. Rep."},{"key":"12104_CR27","first-page":"2694","volume":"10","author":"MA Cenci","year":"1998","unstructured":"Cenci, M. A., Lee, C. S. & Bjorklund, A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10, 2694\u20132706 (1998).","journal-title":"Eur J Neurosci"},{"key":"12104_CR28","doi-asserted-by":"publisher","first-page":"176573","DOI":"10.1016\/j.ejphar.2024.176573","volume":"973","author":"HY Park","year":"2024","unstructured":"Park, H. Y. et al. Angiotensin-converting enzyme inhibition prevents l-dopa-induced dyskinesia in a 6-ohda-induced mouse model of Parkinson\u2019s disease. Eur. J. Pharmacol. 973, 176573 (2024).","journal-title":"Eur. J. Pharmacol."},{"key":"12104_CR29","doi-asserted-by":"publisher","first-page":"5715","DOI":"10.1007\/s12035-017-0752-7","volume":"55","author":"YK Ryu","year":"2018","unstructured":"Ryu, Y. K. et al. Metformin inhibits the development of L-DOPA-induced dyskinesia in a murine model of Parkinson\u2019s disease. Mol. Neurobiol. 55, 5715\u20135726 (2018).","journal-title":"Mol. Neurobiol."},{"key":"12104_CR30","doi-asserted-by":"publisher","first-page":"11744","DOI":"10.1523\/JNEUROSCI.0864-14.2014","volume":"34","author":"HY Park","year":"2014","unstructured":"Park, H. Y. et al. Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson\u2019s disease. J. Neurosci. 34, 11744\u201311753 (2014).","journal-title":"J. Neurosci."},{"key":"12104_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","volume":"194","author":"M Lundblad","year":"2005","unstructured":"Lundblad, M. et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp. Neurol. 194, 66\u201375 (2005).","journal-title":"Exp. Neurol."},{"key":"12104_CR32","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1523\/JNEUROSCI.0837-12.2012","volume":"32","author":"C Alcacer","year":"2012","unstructured":"Alcacer, C. et al. Galpha(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J. Neurosci. 32, 5900\u20135910 (2012).","journal-title":"J. Neurosci."},{"key":"12104_CR33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.tins.2017.04.001","volume":"40","author":"HDE Booth","year":"2017","unstructured":"Booth, H. D. E., Hirst, W. D. & Wade-Martins, R. The role of astrocyte dysfunction in Parkinson\u2019s disease pathogenesis. Trends Neurosci. 40, 358\u2013370 (2017).","journal-title":"Trends Neurosci."},{"key":"12104_CR34","doi-asserted-by":"publisher","first-page":"105028","DOI":"10.1016\/j.nbd.2020.105028","volume":"144","author":"TI Kam","year":"2020","unstructured":"Kam, T. I., Hinkle, J. T., Dawson, T. M. & Dawson, V. L. Microglia and astrocyte dysfunction in parkinson\u2019s disease. Neurobiol. Dis. 144, 105028 (2020).","journal-title":"Neurobiol. Dis."},{"key":"12104_CR35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0079-6123(08)61770-7","volume":"94","author":"LS Forno","year":"1992","unstructured":"Forno, L. S., DeLanney, L. E., Irwin, I., Di Monte, D. & Langston, J. W. Astrocytes and Parkinson\u2019s disease. Prog. Brain Res. 94, 429\u2013436 (1992).","journal-title":"Prog. Brain Res."},{"key":"12104_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0079-6123(10)83011-0","volume":"183","author":"MA Cenci","year":"2010","unstructured":"Cenci, M. A. & Konradi, C. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog. Brain Res. 183, 209\u2013233 (2010).","journal-title":"Prog. Brain Res."},{"key":"12104_CR37","doi-asserted-by":"publisher","first-page":"753279","DOI":"10.3389\/fcell.2021.753279","volume":"9","author":"M Achour","year":"2021","unstructured":"Achour, M., Ferdousi, F., Sasaki, K. & Isoda, H. Luteolin modulates neural stem cells fate determination: In vitro study on human neural stem cells, and in vivo study on LPS-Induced depression mice model. Front Cell Dev Biol 9, 753279 (2021).","journal-title":"Front Cell Dev Biol"},{"key":"12104_CR38","doi-asserted-by":"publisher","first-page":"21824","DOI":"10.1073\/pnas.1012071107","volume":"107","author":"S Fasano","year":"2010","unstructured":"Fasano, S. et al. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc. Natl. Acad. Sci. U S A 107, 21824\u201321829 (2010).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"12104_CR39","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1111\/j.1471-4159.2006.03696.x","volume":"96","author":"M Carta","year":"2006","unstructured":"Carta, M. et al. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 96, 1718\u20131727 (2006).","journal-title":"J. Neurochem."},{"key":"12104_CR40","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1126\/science.aaa7945","volume":"349","author":"R Martin","year":"2015","unstructured":"Martin, R., Bajo-Graneras, R., Moratalla, R., Perea, G. & Araque, A. Circuit-specific signaling in astrocyte-neuron networks in basal ganglia pathways. Science 349, 730\u2013734 (2015).","journal-title":"Science"},{"key":"12104_CR41","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrn2471","volume":"9","author":"P Jenner","year":"2008","unstructured":"Jenner, P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 9, 665\u2013677 (2008).","journal-title":"Nat. Rev. Neurosci."},{"key":"12104_CR42","doi-asserted-by":"publisher","first-page":"108173","DOI":"10.1016\/j.neuropharm.2020.108173","volume":"175","author":"YK Ryu","year":"2020","unstructured":"Ryu, Y. K. et al. Metformin regulates astrocyte reactivity in Parkinson\u2019s disease and normal aging. Neuropharmacology 175, 108173 (2020).","journal-title":"Neuropharmacology"},{"key":"12104_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00401-007-0244-3","volume":"114","author":"H Braak","year":"2007","unstructured":"Braak, H., Sastre, M. & Del Tredici, K. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson\u2019s disease. Acta Neuropathol. 114, 231\u2013241 (2007).","journal-title":"Acta Neuropathol."},{"key":"12104_CR44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41582-023-00822-1","volume":"19","author":"R Patani","year":"2023","unstructured":"Patani, R., Hardingham, G. E. & Liddelow, S. A. Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. Nat Rev Neurol 19, 395\u2013409 (2023).","journal-title":"Nat Rev Neurol"},{"key":"12104_CR45","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1093\/brain\/awad064","volume":"146","author":"KML Cramb","year":"2023","unstructured":"Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J. & Wade-Martins, R. Impaired dopamine release in Parkinson\u2019s disease. Brain 146, 3117\u20133132 (2023).","journal-title":"Brain"},{"key":"12104_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mam.2004.09.004","volume":"26","author":"AJ Duncan","year":"2005","unstructured":"Duncan, A. J. & Heales, S. J. Nitric oxide and neurological disorders. Mol. Aspects Med. 26, 67\u201396 (2005).","journal-title":"Mol. Aspects Med."},{"key":"12104_CR47","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1749-6632.2003.tb07478.x","volume":"991","author":"EC Hirsch","year":"2003","unstructured":"Hirsch, E. C. et al. The role of glial reaction and inflammation in Parkinson\u2019s disease. Ann. N Y Acad. Sci. 991, 214\u2013228 (2003).","journal-title":"Ann. N Y Acad. Sci."},{"key":"12104_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0306-4522(95)00578-1","volume":"72","author":"S Hunot","year":"1996","unstructured":"Hunot, S. et al. Nitric oxide synthase and neuronal vulnerability in Parkinson\u2019s disease. Neuroscience 72, 355\u2013363 (1996).","journal-title":"Neuroscience"},{"key":"12104_CR49","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1093\/brain\/awr165","volume":"134","author":"KE Ohlin","year":"2011","unstructured":"Ohlin, K. E. et al. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain 134, 2339\u20132357 (2011).","journal-title":"Brain"},{"key":"12104_CR50","doi-asserted-by":"publisher","first-page":"9448","DOI":"10.1523\/JNEUROSCI.0944-06.2006","volume":"26","author":"JE Westin","year":"2006","unstructured":"Westin, J. E. et al. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J. Neurosci. 26, 9448\u20139461 (2006).","journal-title":"J. Neurosci."},{"key":"12104_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cells12141859","author":"OF Elabi","year":"2023","unstructured":"Elabi, O. F., Espa, E., Skovgard, K., Fanni, S. & Cenci, M. A. Ropinirole cotreatment prevents perivascular glial recruitment in a rat model of L-DOPA-induced dyskinesia. Cells https:\/\/doi.org\/10.3390\/cells12141859 (2023).","journal-title":"Cells"},{"key":"12104_CR52","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3389\/fncel.2017.00427","volume":"11","author":"S Guerra-Gomes","year":"2017","unstructured":"Guerra-Gomes, S., Sousa, N., Pinto, L. & Oliveira, J. F. Functional roles of astrocyte calcium elevations: from synapses to behavior. Front Cell Neurosci. 11, 427 (2017).","journal-title":"Front Cell Neurosci."},{"key":"12104_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.05.002","author":"A Adamsky","year":"2018","unstructured":"Adamsky, A. et al. Astrocytic activation generates De Novo neuronal potentiation and memory enhancement. Cell https:\/\/doi.org\/10.1016\/j.cell.2018.05.002 (2018).","journal-title":"Cell"},{"key":"12104_CR54","doi-asserted-by":"publisher","first-page":"e00822","DOI":"10.1002\/prp2.822","volume":"9","author":"JH Kim","year":"2021","unstructured":"Kim, J. H., Rahman, M. H., Lee, W. H. & Suk, K. Chemogenetic stimulation of the G(i) pathway in astrocytes suppresses neuroinflammation. Pharmacol. Res. Perspect. 9, e00822 (2021).","journal-title":"Pharmacol. Res. Perspect."},{"key":"12104_CR55","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13041-024-01126-1","volume":"17","author":"T Ogino","year":"2024","unstructured":"Ogino, T. et al. Astrocytic activation increases blood flow in the adult olfactory bulb. Mol Brain 17, 52 (2024).","journal-title":"Mol Brain"},{"key":"12104_CR56","doi-asserted-by":"publisher","unstructured":"Evans, W. R. et al. Functional activation of dorsal striatum astrocytes improves movement deficits in hemi-parkinsonian mice. bioRxiv (2024). https:\/\/doi.org:https:\/\/doi.org\/10.1101\/2024.04.02.587694","DOI":"10.1101\/2024.04.02.587694"},{"key":"12104_CR57","first-page":"321406","volume":"2012","author":"MY Inyushin","year":"2012","unstructured":"Inyushin, M. Y. et al. L-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain. Parkinsons Dis 2012, 321406 (2012).","journal-title":"Parkinsons Dis"},{"key":"12104_CR58","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/1568007053544084","volume":"4","author":"T Asano","year":"2005","unstructured":"Asano, T. et al. Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr. Drug. Targets CNS Neurol. Disord. 4, 127\u2013142 (2005).","journal-title":"Curr. Drug. Targets CNS Neurol. Disord."},{"key":"12104_CR59","doi-asserted-by":"publisher","first-page":"1253273","DOI":"10.3389\/fimmu.2023.1253273","volume":"14","author":"F Zhang","year":"2023","unstructured":"Zhang, F. et al. Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation. Front Immunol. 14, 1253273 (2023).","journal-title":"Front Immunol."},{"key":"12104_CR60","doi-asserted-by":"publisher","first-page":"e106362","DOI":"10.1371\/journal.pone.0106362","volume":"9","author":"M Asanuma","year":"2014","unstructured":"Asanuma, M., Miyazaki, I., Murakami, S., Diaz-Corrales, F. J. & Ogawa, N. Striatal astrocytes act as a reservoir for L-DOPA. PLoS ONE 9, e106362 (2014).","journal-title":"PLoS ONE"},{"key":"12104_CR61","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41392-023-01628-9","volume":"8","author":"A Verkhratsky","year":"2023","unstructured":"Verkhratsky, A. et al. Astrocytes in human central nervous system diseases: a frontier for new therapies. Signal Transduct. Target Ther. 8, 396 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"12104_CR62","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1126\/science.8493557","volume":"260","author":"LF Lin","year":"1993","unstructured":"Lin, L. F., Doherty, D. H., Lile, J. D., Bektesh, S. & Collins, F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130\u20131132 (1993).","journal-title":"Science"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12104-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12104-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12104-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T18:03:15Z","timestamp":1757268195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12104-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12104"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12104-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Institutional Animal Use and Care Committee of the Korea Research Institute of Bioscience and Biotechnology. Mouse care and use were in accordance with the National Institutes of Health Guidance for the Care and Use of Laboratory Animals (protocol number KRIBB-AEC-20065).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors have read and approved the manuscript and consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26635"}}